253 related articles for article (PubMed ID: 8522960)
1. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.
Gudelsky GA; Nash JF
J Neurochem; 1996 Jan; 66(1):243-9. PubMed ID: 8522960
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.
Shankaran M; Yamamoto BK; Gudelsky GA
Eur J Pharmacol; 1999 Dec; 385(2-3):103-10. PubMed ID: 10607865
[TBL] [Abstract][Full Text] [Related]
3. MDMA induced dopamine release in vivo: role of endogenous serotonin.
Koch S; Galloway MP
J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
[TBL] [Abstract][Full Text] [Related]
4. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479
[TBL] [Abstract][Full Text] [Related]
5. Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions.
Goñi-Allo B; Ramos M; Herv'as I; Lasheras B; Aguirre N
J Psychopharmacol; 2006 Mar; 20(2):245-56. PubMed ID: 16510482
[TBL] [Abstract][Full Text] [Related]
6. 2-Deoxy-D-glucose prevents and nicotinamide potentiates 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity.
Hervías I; Lasheras B; Aguirre N
J Neurochem; 2000 Sep; 75(3):982-90. PubMed ID: 10936179
[TBL] [Abstract][Full Text] [Related]
7. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
Kanthasamy A; Sprague JE; Shotwell JR; Nichols DE
Neuroscience; 2002; 114(4):917-24. PubMed ID: 12379247
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.
Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR
Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492
[TBL] [Abstract][Full Text] [Related]
9. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats.
O'Shea E; Escobedo I; Orio L; Sanchez V; Navarro M; Green AR; Colado MI
Neuropsychopharmacology; 2005 Jul; 30(7):1312-23. PubMed ID: 15688085
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat.
Nair SG; Gudelsky GA
Brain Res; 2004 Jul; 1013(2):168-73. PubMed ID: 15193525
[TBL] [Abstract][Full Text] [Related]
11. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.
Baumann MH; Clark RD; Rothman RB
Pharmacol Biochem Behav; 2008 Aug; 90(2):208-17. PubMed ID: 18403002
[TBL] [Abstract][Full Text] [Related]
12. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons.
Mlinar B; Corradetti R
Eur J Neurosci; 2003 Sep; 18(6):1559-71. PubMed ID: 14511335
[TBL] [Abstract][Full Text] [Related]
13. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain.
Riegert C; Wedekind F; Hamida SB; Rutz S; Rothmaier AK; Jones BC; Cassel JC; Jackisch R
Int J Neuropsychopharmacol; 2008 Sep; 11(6):743-63. PubMed ID: 18248690
[TBL] [Abstract][Full Text] [Related]
14. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Yamamoto BK; Nash JF; Gudelsky GA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.
Nixdorf WL; Burrows KB; Gudelsky GA; Yamamoto BK
J Neurochem; 2001 Apr; 77(2):647-54. PubMed ID: 11299327
[TBL] [Abstract][Full Text] [Related]
16. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
[TBL] [Abstract][Full Text] [Related]
17. Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone.
Johnson BN; Yamamoto BK
Neuroscience; 2009 Apr; 159(4):1233-43. PubMed ID: 19409219
[TBL] [Abstract][Full Text] [Related]
18. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
Callaghan PD; Irvine RJ; Daws LC
Neurochem Int; 2005 Oct; 47(5):350-61. PubMed ID: 15979209
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists.
Gudelsky GA; Yamamoto BK; Nash JF
Eur J Pharmacol; 1994 Nov; 264(3):325-30. PubMed ID: 7698172
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA.
Barrionuevo M; Aguirre N; Del Río JD; Lasheras B
Pharmacol Biochem Behav; 2000 Feb; 65(2):233-40. PubMed ID: 10672974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
